Jubilant Pharmova Ltd.

NSE: JUBLPHARMA | BSE: 530019 | ISIN: INE700A01033 | Industry: Pharmaceuticals
| Strong Performer
1194.0000 -7.50 (-0.62%)
NSE Jul 04, 2025 15:31 PM
Volume: 169.8K
 

1194.00
-0.62%
Prabhudas Lilladhar
We reduce earnings estimate of JUBILANT by 23%17.5%11.6% for FY21/22/23E due to weak and inconsistent performance of its Pharmaceutical segment (65% revenue and 78% EBITDA contribution in FY20) whose key contributors Radio pharma and Allergy are currently witnessing lower volumes caused by pandemic in US. Radiopharma being a hospital driven...
Number of FII/FPI investors increased from 185 to 196 in Mar 2025 qtr.
More from Jubilant Pharmova Ltd.
Recommended